United States Vaccine Market Report and Forecast 2024-2032

United States Vaccine Market Report and Forecast 2024-2032

Market Outlook

According to the report the United States vaccine market is projected to grow at a CAGR of 9.8% between 2024 and 2032 to reach a value of about USD 32.87 billion by 2032. Aided by the technological advancements, an increasing focus on preventive healthcare, and a heightened awareness of infectious diseases, the market is expected to grow significantly by 2032.

Vaccines play a crucial role in public health, offering protection against various infectious diseases. In the United States, the vaccine market encompasses a broad range of products, including vaccines for influenza, pneumococcal disease, human papillomavirus (HPV), and a growing portfolio of vaccines for emerging infectious diseases. The demand for these vaccines is driven by a combination of government initiatives, public health campaigns, and a general increase in health consciousness among the populace.

The United States vaccine market outlook is being influenced by the well-established paediatric vaccination program. The routine immunisation schedule recommended by the Centres for Disease Control and Prevention (CDC) has ensured a steady demand for vaccines among children. The adult vaccine segment, though smaller, is also experiencing growth due to the increasing adoption of vaccines for shingles, pneumococcal disease, and HPV among others.

The market is also witnessing an expanding role of public-private partnerships and government funding in vaccine development and distribution. According to the United States vaccine market analysis, these collaborations are crucial in addressing public health needs, especially in the context of emerging infectious diseases and pandemic preparedness. The government's involvement in vaccine procurement and distribution, along with initiatives to ensure vaccine equity and accessibility, is a significant factor driving market growth.

Moreover, there is an increasing need for educational campaigns to address vaccine hesitancy, opening avenues for public health initiatives and collaborations which in turn is boosting the United States vaccine market demand. Moreover, advancements in vaccine storage and delivery systems, such as portable cold storage solutions, offer opportunities for innovation in the logistics and supply chain aspects of the market.

Another opportunity lies in the development of combination vaccines, which can protect against multiple diseases with a single shot. These vaccines are particularly appealing in paediatric immunisation, offering convenience and improved compliance. Additionally, the growing interest in personalised vaccines, tailored to individual genetic profiles, presents a frontier for innovation and market expansion.

Market Segmentation

The market can be divided based on technology, indication, end use, and region.

Market Breakup by Technology

• Recombinant and Conjugate Vaccine
• Inactivated Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Others

Market Breakup by Indication

• Pneumococcal Disease
• Influenza
• Human Papilloma Virus
• Meningococcal Disease
• Rotavirus
• Varicella, Measles, Mumps, and Rubella
• Diphtheria, Pertussis, and Tetanus (DPT)
• Polio
• Hepatitis
• Others

Market Breakup by End Use

• Paediatric Vaccine
• Adult Vaccine
• Travellers Vaccine

Market Breakup by Region

• New England
• Mideast
• Great Lakes
• Plains
• Southeast
• Southwest
• Rocky Mountain
• Far West

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the United States vaccine market. Some of the major players explored in the report are as follows:

• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Others